TCRX Q2 2025 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+473.9% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$39M-1256.6% margin

Net Income

-$37M-1201.3% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+41.7%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$35M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$299M

Total Liabilities

$122M

Stockholders' Equity

$177M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$536,000	+473.9%
Gross Profit	$3M	$536,000	+473.9%
Operating Income	-$39M	-$34M	-13.3%
Net Income	-$37M	-$32M	-16.7%

Revenue Segments

Reportable Segment

$3M100%